Choline fenofibrate is a newly developed choline salt of fenofibric acid, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity that acts as an PPARα agonist.
|Solubility (25°C)||DMSO 5 mg/mL
Water 9 mg/mL
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Myung Soo Park, et al. Clin Ther. Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study
 Sander Lefere, et al. J Hepatol. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆
 No authors listed. Fenofibrate
 Mukul R Jain, et al. Liver Int. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
 Piyush Patel, et al. Indian J Endocrinol Metab. Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
|Related PPAR Products|
AZD-9574 is a potent blood-brain barrier permeability inhibitor of PARP1, showing > 8,000 times selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 selectively inhibits PARP1 at the SSB site. AZD-9574 is an anticancer compound that can be used in HRD+ breast cancer and advanced solid malignancies.
Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) is a PPARγ agonist that provides high transcriptional potency by stabilizing the PPARγ (AF-2) coactivator binding surface and enhancing coactivator binding capacity. Leriglitazone (Hydroxypioglitazone) binds to PPARγC (LBD) with a Ki value of 1.2 μM and induces PPARγ (LBD) transcriptional efficiency with an EC50 of 680 nM.
an agonist of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
GW1929 is a potent PPAR-γ agonist, with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.